Press

Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market

Nov 17 • 3 min read

Clearmind Medicine Inc. (Nasdaq and CSE: CMND | FSE: CWY0), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced the closing of its underwritten public offering of 1,153,847 common shares at a price to the public of US$6.50 per share (CAD$8.65), for aggregate gross…

MAPS PBC Completes Second Phase 3 “MAPP2” Trial of MDMA-Assisted Therapy for Treatment of PTSD

Nov 17 • 3 min read

MAPS Public Benefit Corporation (“MAPS PBC”), a private company dedicated to the development and commercialization of psychedelic medicines, announced the final participant visit has been completed in MAPP2, a multi-site Phase 3 study of MDMA-assisted therapy (“MDMA-AT”) for post-traumatic stress disorder (“PTSD”). The top-line results are expected in the first quarter of 2023. This is…

Filament Health Announces Psilocybin Supply Agreement With the Centre for Addiction and Mental Health

Nov 17 • 2 min read

Filament Health Corp. (OTCQB: FLHLF | NEO: FH) (FSE: 7QS), a clinical‐stage natural psychedelic drug development company, today announced an agreement with the Centre for Addiction and Mental Health (CAMH), Canada’s largest mental health teaching hospital and one of the world’s leading research centres in the field. Filament will supply CAMH with its natural psilocybin drug candidate for…

Albert Labs signs Letter of Intent (LOI) with iNGENū CRO for First In-Human Clinical Studies

Nov 17 • 4 min read

Albert Labs International Corp. (CSE: ABRT | FSE: VB50), a pharmaceutical drug development company focused on gaining regulatory approval for novel medicines to treat various mental health conditions, signs a Letter of Intent (LOI) with full-service Contract-Research Organisation (CRO), iNGENū, to carry out the Company’s first in-human study of its primary drug target, KRN-101. This randomised, double-blind…

Numinus to Host Q4 and Year End 2022 Results Conference Call on November 29, 2022

Nov 16 • 2 min read

Numinus Wellness Inc. (TSX: NUMI | OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter and year ended August 31, 2022, after market close on Tuesday, November 29, 2022. Interested parties are invited to participate in the Company’s Q4 and year end 2022 results…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435